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Abstract
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small cell lung cancer, especially
adenocarcinoma. Tumors with EGFR mutations showed good response to EGFR tyrosine kinase inhibitors (TKIs). We aimed
to identify the discriminating capacity of immunohistochemical (IHC) scoring to detect L858R and E746-A750 deletion
mutation in lung adenocarcinoma patients and predict EGFR TKIs response. Patients with surgically resected lung
adenocarcinoma were enrolled. EGFR mutation status was genotyped by PCR and direct sequencing. Mutation-specific
antibodies for L858R and E746-A750 deletion were used for IHC staining. Receiver operating characteristic (ROC) curves
were used to determine the capacity of IHC, including intensity and/or quickscore (Q score), in differentiating L858R and
E746-A750 deletion. We enrolled 143 patients during September 2000 to May 2009. Logistic-regression-model-based
scoring containing both L858R Q score and total EGFR expression Q score was able to obtain a maximal area under the
curve (AUC: 0.891) to differentiate the patients with L858R. Predictive model based on IHC Q score of E746-A750 deletion
and IHC intensity of total EGFR expression reached an AUC of 0.969. The predictive model of L858R had a significantly
higher AUC than L858R intensity only (p=0.036). Of the six patients harboring complex EGFR mutations with classical
mutation patterns, five had positive IHC staining. For EGFR TKI treated cancer recurrence patients, those with positive
mutation-specific antibody IHC staining had better EGFR TKI response (p=0.008) and longer progression-free survival
(p=0.012) than those without. In conclusion, total EGFR expression should be included in the IHC interpretation of L858R.
After adjusting for total EGFR expression, the scoring method decreased the false positive rate and increased diagnostic
power. According to the scoring method, the IHC method is useful to predict the clinical outcome and refine personalized
therapy.
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Introduction
Epidermal growth factor receptor (EGFR), a member of the
ErbB family, is a transmembrane glycoprotein [1]. Non-small cell
lung cancer (NSCLC) patients with EGFR mutations have had a
dramatic response to EGFR tyrosine kinase inhibitors (EGFR
TKIs) [2,3]. The patients who have shown a good response to
EGFR TKIs have been mainly from particular groups, including
female, adenocarcinoma histology, non-smokers and Asian
ethnicity [3,4,5]. Approximately 90% of EGFR mutation types
have been found to be a point mutation of L858R in exon 21 and
an in-frame deletion in exon 19 (Del-19), especially the E746-A750
deletion [6]. They are the most well-known EGFR TKI sensitive
mutations and are also known as ‘‘classical mutations’’. It is
important to select patients with tumors harboring EGFR
mutations when using EGFR TKIs. For EGFR mutation analysis,
different molecular techniques such as direct DNA sequencing and
scorpion amplified refractory mutation systems (ARMS) have been
used [7], but they are time-consuming, expensive and complicat-
ed, and thus not routinely used in general hospitals or clinical
laboratories.
Yu et al. developed mutation-specific rabbit monoclonal
antibodies against the E746-A750 deletion and L858R mutation
of EGFR [8]. Immunohistochemistry (IHC) is a well-established
method, and is applied broadly in routine biopsy tissue diagnosis in
clinical practice. It can also be applied in small tissue samples, fine
needle aspiration cytology and cell blocks from body fluids. This
simple assay is a rapid and cost-effective method, and it can be
used as screening to identify most candidates who may have a
favorable response to EGFR TKIs [8,9]. The sensitivity and
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23303specificity of the mutation-specific antibodies of EGFR have been
confirmed [8,10]. However, the range of the overall sensitivity has
been found to be from 47% to 92% in different studies using the
same antibodies [8,11].
Although the IHC approach can support the routine assessment
of specific EGFR mutations, different scoring schemes of IHC
staining have also been adopted. Most of the published studies
have used an intensity scoring method [8,9,10,11,12], although the
University of Colorado’s IHC H-score criteria and other scoring
systems have also been adopted [13,14]. However, no statistical
methodology has been used to confirm whether or not the scoring
method of IHC intensity is optimal. Furthermore, Kitamura et al.
reported that a positive reaction to the two mutation-specific
antibodies was associated with the expression of total EGFR by
EGFR antibody [11]. However, there have not been any studies
focusing on whether total EGFR expression level has any influence
on the IHC interpretation of the two EGFR mutation-specific
antibodies.
The prior reports have shown variable sensitivity and specificity
to detect activating EGFR mutations by the EGFR mutation-
specific antibodies[8,10,11,13,14]. In addition, the role of IHC-
based EGFR mutations to predict clinical response and progression
free survival to EGFR TKIs was still controversial [11,13,14]. For
this reason. the aim of this study was to identify the discriminating
capacity of IHC scoring for the detection of the two specific EGFR
mutations, L858R and E746-A750 deletion, in patients with
adenocarcinoma of the lung. The impact of total EGFR
expression was considered into the analysis of the scoring
assessment. The clinical outcomes, including time to tumor
recurrence and EGFR TKI treatment outcomes were also studied.
Materials and Methods
Patients and tissue procurement
We collected surgically resected lung tumors at the National
Taiwan University Hospital (Taipei, Taiwan) from September
2000 to May 2009. Patients with paraffin-embedded surgically
resected lung tumor specimens, histologically confirmed lung
adenocarcinoma were included. Informed consent about the use of
these specimens for future molecular studies was obtained before
surgery after approval of the Institutional Review Board (IRB).
(the IRB approval number: 993703374) The paraffin-embedded
tissues were collected for EGFR sequencing and IHC staining of
EGFR mutation-specific antibodies.
The histology of lung cancer was classified according to the
World Health Organization pathology classification [15]. All of the
lung cancer patients received complete lung cancer staging work-up
as a routine practice before surgery, which included computed
tomography (CT) of the head, chest and abdomen, and whole body
bone scintigraphy.Thedisease stage was determinedbythe Tumor-
Node-Metastasis system for NSCLC staging [16]. The dates of
diagnosis, surgical excision, tumor recurrence and survival were
recorded. All systemic treatments as adjuvant treatment or after
tumor recurrence, including chemotherapy and EGFR TKIs, and
responsiveness to the treatment were recorded.
Clinical data, including demographic information and smoking
status, were recorded, and imaging studies were collected.
Smoking status was defined as non-smokers (,100 cigarettes in
the patient’s lifetime), current smokers (patients smoking with 1
year of diagnosis), and former smokers (all others).
Response evaluation of lung adenocarcinoma patients
We reviewed all patients’ image studies during the whole disease
course. The unidimensional method was used according to the
Response Evaluation Criteria in Solid Tumor guidelines to
evaluate measurable solid tumors [17]. Only patients with a
complete response (CR) and partial response (PR) were regarded
as responders. Time to tumor recurrence was measured from the
date of operation until the first date of tumor recurrence via
imaging studies. Progression-free survival (PFS) was calculated
from the date of initiation of the EGFR TKI treatment until the
first objective or clinical sign of disease progression or death.
Sequencing of EGFR exons 18–21
The surgically resected tumor sections were first evaluated with
hematoxylin and eosin staining. Macrodissection was performed to
make the tissue samples consist of more than 80% cancer cells.
DNA was extracted using a QIAmp DNA Mini Kit (Qiagen,
Valencia, CA) for EGFR mutation analysis. The tyrosine kinase
domain of the EGFR coding sequence, exons 18, 19, 20, and 21
were amplified by nested PCRs from DNA, and PCR amplicons
were purified as described previously [18,19,20].
PCR amplicons were sequenced in both the sense and antisense
directions and chromatograms were examined manually. EGFR
mutations detected in the initial round of sequencing were
confirmed by independent PCR and sequencing reactions. Only
specimens in which a mutation was identified in both rounds were
recorded as mutation-positive.
Table 1. Clinical characteristics and EGFR DNA sequencing
results.
Variable
Total
patients (%)
Total No. 143 100
Age median 65.2
(range) (27.2–86.9)
Sex
Female 72 50.3
Male 71 49.7
Smoking
Non-smoker 94 65.7
Former/current smoker 49 34.3
Initial Stage
I 74 51.7
II 21 14.7
III 46 32.2
IV 2 1.4
EGFR mutation
E746-A750 deletion 31 21.7
Other Del-19 10 7.0
L858R* 43 30.1
Others# 8 5.6
Wild 50 35.0
*Including: two L858R+V834L, one L858R+E709V, one L858R+T790M and one
L858R+ K757N.
#Including: two L861Q, one E709K+G719A, one E709K+G719S, one
G719A+L861Q, one N771-H773 dupNPH, one K860I+861Q, and one
R831C+L861R.
Two patients received cranial tumor excision for solitary brain metastasis and
lobectomy for a pulmonary nodule.
doi:10.1371/journal.pone.0023303.t001
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concomitant different EGFR mutations. When the complex EGFR
mutation had either an in-frame Del-19 or a point mutation L858R
in exon 21, it was defined as a ‘‘classical mutation pattern’’ [21].
Immunohistochemistry for EGFR mutations
4-mm sections were cut from the paraffin-embedded tissue
samples of the surgically resected lung adenocarcinomas. Antigen
retrieval by AR-10 Solution (EDTA buffer) (Biogenex San Ramon,
CA) was performed at 121uC for 10 minutes. The commercial
monoclonal antibodies, including L858R (clone 43B2) and E746-
A750 deletion (clone 6B6) (Cell Signaling Technology, Danvers,
MA), were applied (dilution 1:150 for both antibodies) and the
slides incubated overnight at 4uC. A diaminobenzidine (DAB)
(BioGenex, San Ramon, CA) detection kit was used with extra
washing steps selected. The slides were then counter-stained with
hematoxylin for 3 minutes. We also performed IHC staining for
total EGFR protein using the monoclonal EGFR mouse antibody
(clone 31G7, dilution 1:150, Invitrogen, CA). Control IHC
staining for pan-cytokeratin was performed using the anti-
cytokeratin cocktail (clones AE1/AE3, dilution 1:100, BioGenex,
CA) according to the manufacturer’s instructions.
IHC scoring assessments
The intensity and percentage of IHC staining were recorded.
The intensity was scored from 0 to 3+ and defined as follows: 0, no
staining; 1+, weak staining; 2+, moderate staining; 3+, strong
staining based on the staining score [8].
In addition, the quickscore (Q score) based on estimating the
percentage (P) of tumor cells showing characteristic staining (0–
100%) and by estimating the intensity (I) of staining was adopted
for IHC scoring. The slides were scored by multiplying the
percentage of positive cells by the intensity (Q=P6I; maximum
=300) [22].
An overview of the IHC for all tissue sections was performed by
two pathologists (YL Chang and CT Wu). Two observers
evaluated the staining results independently and differences in
interpretation were resolved by consensus.
Statistical analysis
All categorical variables were analyzed with Pearson’s x2 tests,
except where a small size required the use of Fisher’s exact test.
Univariate analysis of the patient characteristics was used to
identify the predictive factors of EGFR TKI response. The time to
tumor recurrence, PFS curve were plotted by the Kaplan-Meier
method and compared by a log-rank test. Multivariate analysis for
PFS was performed using Cox linear regression method. Two-
sided p values of less than 0.05 were considered significant. A
binary logistic regression model based on the IHC intensity/Q
score of EGFR mutation-specific antibodies and total EGFR
expression was used to predict the probability of L858R/E746-
A750 deletion from direct sequencing. Receiver operating
Figure 1. Immunohistochemical stain of lung adenocarcinoma. Control pan-cytokeratin antibody stains all tissue samples regardless of EGFR
mutation status. Case 1. A sample with wild-type EGFR was not stained with total EGFR, L858R and delE746-A750 antibodies. Case 2. A sample with
delE746-A750 was stained with both total EGFR and delE746-A750 specific antibody. Case 3. A sample with L858R was stained with both total EGFR
and L858R specific antibody. Case 4. A sample with wild-type EGFR was stained with moderate intensity of total EGFR and mild intensity of L858R
specific antibody.
doi:10.1371/journal.pone.0023303.g001
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scoring methods. The best area under the ROC curves (AUC) was
used to determine the best IHC scoring system and the correlative
optimal cut-off point of IHC staining. All analyses were performed
using the SPSS software package (version 17.0 for Windows; SPSS
Inc.) and SAS 9.2 (SAS Institute Inc.).
Results
Clinical characteristics and EGFR DNA sequencing status
of the lung adenocarcinoma patients
A total of 157 paraffin-embedded specimens of surgically
resected lung adenocarcinomas were consecutively collected from
September 2000 to May 2009. No patients received neoadjuvant
chemotherapy before the tumor resection. There were 23 patients
who received adjuvant chemotherapy. Fourteen sections had less
than 60% tumor cells and were therefore excluded. In total, 143
samples were enrolled in this study.
Of the 143 adenocarcinoma patients, there were 72 females and
71 males with a median age of 65.2 years (range: 27.2–86.9 years).
Ninety-four patients (65.7%) were non-smokers. The clinical
characteristics of these patients are shown in Table 1. DNA
sequencing showed EGFR mutations in 93 patients (65.0%),
including 41 Del-19 (28.7%), 43 L858R (30.1%) and 8 other
mutations(5.6%).Thirty-oneofthe41Del-19patients(75.6%)hada
deletion in the range of E746-A750 (Supporting Information Table
S1). Females (female: 79.2% versus (vs.) male: 50.7%; p,0.001) and
non-smokers (non-smokers: 77.7% vs. former/current smokers:
40.8%; p,0.001) had higher EGFR mutation rates.
IHC results of lung adenocarcinomas
The mutation-specific antibodies (L858R point mutation and
E746-A750 deletion in exon 19), total EGFR antibody and pan-
cytokeratin were used to stain the 143 tumor sections. IHC with
pan-cytokeratin was positive to confirm the reactivity of the tissues
for IHC and verify the quality of theses tissue samples (Figure 1).
The mutation-specific antibodies and total EGFR antibody have
distinct immunoreactivity for the tumor cells as presented in
Figure 1. The IHC intensity, Q score and the predictive
probability of the logistic regression model based on specific
antibodies and total EGFR expression were used to construct the
ROC curves and calculate the AUCs (Table 2).
For IHC staining of L858R, the best AUC came from the
predictive probability of the logistic regression model based on the
L858R Q scores and the total EGFR expression Q scores (Table 2).
The best AUC of L858R was 0.891, and the correlative optimal
cut-off point was 0.154 of the predictive probability by the logistic
regression model. According to the optimal cut-off point, the
L858R IHC staining scoring method, which combined L858R Q
scores with total EGFR expression Q scores, showed 88.4%
sensitivity, 77.0% specificity, 62.3% positive predictive value
(PPV), and 93.9% negative predictive value (NPV).
For the E746-A750 deletion, the best AUC came from the
predictive probability of the logistic regression model based on the
IHC Q score of E746-A750 deletion and the IHC intensity of total
EGFR expression (Table 2). The best AUC was 0.969, and the
correlative optimal cut-off point was 0.061 of the predictive
probability by the logistic regression model. According to the
optimal cut-off point, the E746-A750 deletion scoring method,
which combined Q scores of E746-A750 and the intensity of total
EGFR expression, showed 93.5% sensitivity, 94.6% specificity,
82.9% PPV, and 98.1% NPV.
IHC staining with the L858R mutation-specific antibody was
detected in 38 of 43 L858R-mutated cases who were proven by
DNA sequencing. Of the 31 patients with the E746-A750 deletion
by DNA sequencing, IHC staining with the E746-A750 deletion
mutation-specific antibody was detected in 29 patients. For the 10
patients with deletions in exon 19 other than the E746-A750
deletion, one patient with the L747-T751 deletion in exon 19 was
also positive for IHC staining by the E746-A750 deletion specific
antibody (Table 3 and Table S1).
If all deletions in exon-19 in addition to E746-A750 were
considered, the sensitivity, specificity, PPV, and NPV were 73.2%,
95.1%, 85.7%, and 89.8%, respectively (Table 3 and 4). In order
to detect the common EGFR mutations for clinical practice, the
sensitivity and specificity of double staining, including E746-A750
or L858R, were 90.5% and 73.9%, respectively. 83.3% sensitivity
and 74.6% specificity for the detection of any deletion in exon-19
or L858R were noted (Table 4).
There were 11 cases with complex mutations, and six patients
with complex mutations with classical mutation patterns. The
EGFR mutations of these six cases were L858R combined with
another mutation type (Table S1). Five of the six cases had positive
IHC staining with the L858R mutation-specific antibody.
Table 3. Comparison of results of EGFR mutation-specific antibodies and DNA direct sequencing.
IHC for L858R and E746-A750 (N=143)
IHC L858R DNA sequencing for L858R
L858R Non-L858R Total
Positive 38 23 61
Negative 57 7 8 2
Total 43 100 143
IHC delE746-A750 DNA sequencing for Exon 19
delE746-A750 other Non-del 19 Total
Positive 29 1 5 35
Negative 2 9 97 108
Total 31 10 102 143
doi:10.1371/journal.pone.0023303.t003
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system with best AUC
For L858R, the best AUC came from the logistic regression
model based on the L858R Q scores and the total EGFR
expression Q score, and was higher than that of L858R IHC
intensity only (0.891 vs. 0.853; p=0.036) (Figure 2A). For E746-
A750 deletion, the AUC difference did not reach statistical
significance, although the logistic regression model based on E746-
A750 Q score and total EGFR expression IHC intensity had a
higher AUC than E746-A750 intensity only. (0.969 vs. 0.958;
p=0.087) (Figure 2B).
Corresponding table for EGFR mutation status
According to the scoring method with the best AUC and the
correlated best cut-off point, Table S2 and Table S3 of the
Supporting Information illustrate the EGFR genotype based on the
probability of L858R and E746-A750 deletion according to the
logistic regression model with best AUC. The detailed predictive
probabilities for L858R and E746-A750 are listed in Table S4 and
Table S5 (Supporting Information).
Clinical outcome of the lung adenocarcinoma patients
Of the 143 patients, 80 patients suffered from tumor recurrence.
The median time to tumor recurrence was 33.465.8 (median 6
standard error (SE)) months. According to univariate analysis,
tumor size (T1, T2, T3 or T4) (p=0.032), lymph node
involvement (N0, N1 and N2) (p,0.001) and initial stage (stage
I, II, III or IV) (p=0.001) were the factors which had significant
impacts for tumor relapse. In addition, the patients with adjuvant
chemotherapy had less median time to tumor relapse than the
patients without adjuvant chemotherapy (19.0 vs.41.9 months,
p=0.014).
However, there was no difference in time to tumor recurrence
between the patients with IHC positive tumor and those with IHC
negative tumor (IHC (+): 34.5 months vs. IHC (-): 33.4 months;
p=0.742). Sex, age(,=65 or .65 years), smoking history and
Figure 2. Receiver–operator characteristic (ROC) curve of EGFR mutation-specific antibodies IHC in predicting L858R or E746-A750.
(A) AUC for the logistic regression model based on L858R Q score and total EGFR expression Q score was higher than that for L858R intensity only
(0.891 vs. 0.853; p=0.036). (B) the logistic regression model based on delE746-A750 Q score and total EGFR expression intensity had a trend of higher
AUC than that for delE746-A750 intensity only (0.969 vs. 0.958; p=0.087). AUC: area under the ROC curve.
doi:10.1371/journal.pone.0023303.g002
Table 4. The detection accuracy for the EGFR mutation-specific antibodies.
Genotype
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
L858R 88.4% 77.0% 62.3% 93.9%
delE746-A750 93.5% 94.6% 82.9% 98.1%
All Del-19 73.2% 95.1% 85.7% 89.8%
delE746-A750 or L858R 90.5% 73.9% 78.8% 87.9%
del-19 or L858R 83.3% 74.6% 82.4% 75.9%
PPV: positive predictive value; NPV: negative predictive value.
doi:10.1371/journal.pone.0023303.t004
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affected time to tumor relapse for the 143 lung adenocarcinoma
patients by univariate analysis.
Clinical treatment outcomes of EGFR TKIs in the lung
adenocarcinoma patients
Among the 80 patients with tumor recurrence, 37 patients
received EGFR TKIs as the systemic treatment. Twenty-five
patients took gefitinib (250 mg/day) and 12 patients took erlotinib
(150 mg/day). EGFR TKIs were used as first-line treatment for 7
patients (18.9%), second-line treatment for 12 patients (32.4%),
third-line treatment for 14 patients (37.8%), and subsequent-line
treatment for 4 patients (10.8%). No concurrent chemotherapy or
radiotherapy for the lung tumors was performed during EGFR
TKI therapy. Twenty-two patients (59.5%) had a partial response
as maximal response, 4 patients (10.8%) had stable disease and 11
patients (29.7%) had progressive disease. The median follow-up
duration for the PFS analyses was 28.368.9 (median 6 SE)
months.
The EGFR mutations consisted of 14 wild type, 12 Del-19
(including 10 E746-A750 deletions, one L747-P753 deletion and
one delE746-T751 insQ), nine L858R, one delE709-T710 insD
and one R831C + L861R (Table S6). According to the DNA
sequence results, the EGFR mutation-positive patients (n=23) had
a longer PFS than the mutation-negative patients (n=14) (median,
12.0 months vs. 1.7 months; p,0.001).
According to our scoring method with the best AUC, 22
patients had tumors with positive IHC staining and 15 patients
had tumors with negative IHC staining. Of the 22 cases scored
positive with IHC staining, 12 cases were scored positive with the
L858R antibody, 9 cases with the E746-750 deletion antibody,
and one case harboring the E746-A750 deletion by direct
sequence was scored positive with both the L858R and E746-
A750 deletion antibodies. The patients in the positive IHC
staining group had a better response rate than those in the
negative IHC staining group (77.3% (17 of 22) vs. 33.3% (5 of 15);
p=0.008). In addition, the patients in the positive IHC group had
a longer PFS than those in the negative IHC group (median, 12.0
months vs. 4.7 months; p=0.012, by the log-rank test) (Figure 3).
Multivariate analysis was performed by the Cox regression
model for the potential factors, including sex, smoking, ECOG PS
and EGFR IHC results (positive or negative) and line of EGFR
TKI treatment. As a result, ECOG PS 2–4 (Hazard ratio (HR):
5.52, 95% confidence interval (CI): 2.04–14.95; p=0.001) and
positive staining of EGFR IHC (HR: 0.29, 95% CI: 0.12–0.68;
p=0.004) were the independent factors that significantly affected
PFS for the lung adenocarcinoma patients treated with EGFR
TKIs (Table 5).
Discussion
This is the first study to demonstrate the influence of total
EGFR expression on the IHC interpretation of mutation-specific
antibodies, especially L858R, and compare different IHC scoring
methods of mutation-specific antibodies by statistical analysis. The
scoring method based on the logistic regression model provided
the best diagnostic power, and false positive and false negative
rates were both decreased in comparison with the scoring system
of IHC intensity only. In addition, the positive IHC staining
according to the best cut-off point was correlated to a better
response rate to EGFR TKIs and a longer PFS. The IHC test of
the mutation-specific antibodies is useful for personalized therapy.
The majority of published papers have adopted the IHC
intensity scoring method to interpret mutation-specific antibodies,
with the definition of a positive IHC result being more than 10%
tumor cells with an IHC intensity score of 1+ or more
[8,9,10,11,12]. However, Kato et al. ’s study adopted the
Figure 3. Kaplan-Meier survival curve of progression-free survival after EGFR TKIs. The patients with tumors with positive stains of EGFR
mutation (solid line, N=22) had a longer progression-free survival than those with negative stains of EGFR mutation (dashed, N=17) (median, 12.0
months vs. 4.7 months; p=0.012, by the log-rank test).
doi:10.1371/journal.pone.0023303.g003
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adopted another scoring system [13,14]. The sensitivity and
specificity of the mutation-specific antibodies from these scoring
systems showed contrasting results, especially in Kitamura et al. ’s
study where the sensitivity was only 36% for L858R and 40% for
E746-A750 deletion [11]. Compared with the above scoring
method of IHC intensity (1+), the scoring method of the present
study which had the best AUC showed that the false-positive rate
decreased from 42% to 23% for L858R, and from 9.8% to 5.4%
for E746-A750 deletion, and provided better diagnostic power.
The present study demonstrated that total EGFR expression
may affect the IHC interpretation of the L858R antibody. If lung
cancer of wild-type EGFR had a high total EGFR expression Q
score, the L858R mutation antibody had a low level of non-
specific stains (Case 4 of Figure 1). Therefore, when using the
EGFR mutant-specific antibodies for detecting EGFR mutant
lung cancers, side by side IHC with total EGFR antibody is also
necessary for the interpretation of the IHC result of mutation-
specific antibody. These findings provided an usage of IHC with
EGFR total and mutation-specific antibodies to choose the
suitable patients for EGFR TKIs treatment.
The use of IHC staining to predict responses to EGFR TKIs has
been controversial in previous reports [11,13,14]. Kozu Y, et al
showed that the sensitivity and specificity of IHC-based EGFR
mutations to predict response to EGFR TKIs were 63% and 70%,
respectively. Besides, the IHC-based mutational status was not
significantly correlated to clinical response to EGFR TKI by
multivariate analysis [14]. Kato et al. showed that positive IHC
staining of the two mutation-specific antibodies produced a
nonsignificant trend toward a favorable clinical outcome,
including overall survival and PFS [13]. In the present study,
the analysis of clinical treatment outcomes confirms the clinical
practicability and value of IHC staining according to the cut-off
point. Large prospective trials are necessary to prove the clinical
value of mutation-specific antibodies.
According to our prior report, patients with complex EGFR
mutations with the classical mutation pattern had the same
response rate, PFS, and overall survival time as those with a single
classical mutation [21]. It is important to pick up the tumors
harboring complex mutations with classical mutation patterns
when considering the treatment with EGFR TKIs. In the present
study, the mutation-specific antibodies had a high diagnostic
sensitivity (5 of 6, 83.3%) for the tumors harboring complex EGFR
mutations with classical mutation patterns. IHC with EGFR
mutant-specific antibodies could therefore be used to screen this
type of candidate for the use of EGFR TKIs. This probably
implies that the second mutation does not affect the conformation
of classical mutation, and therefore EGFR TKI can inhibit the
activation of complex-mutant EGFR and the mutant-specific
antibody can stain the complex-mutant EGFR.
In the present study, one of four tumors harboring the L747-
T751 deletion was also positive to the E746-A750 deletion
mutation-specific antibody. Although Kitamura et al. mentioned
that this phenomenon may result from the similar conformational
composition to the E746-A750 deletion [11], it cannot completely
explain why the other three tumors harboring the same EGFR
mutation, L747-T751 deletion, could not be detected by IHC
staining. Future studies are required to elucidate the definite
mechanism.
In addition to Del-19 and L858R, EGFR TKIs also lead
favorable response in patients with G719 and L861 [23,24]. It is
important for clinical physician to select patients with sensitive
mutation to EGFR TKIs. However, the present mutation-specific
antibodies were only designed to detect L858R and delE746-
A750. The sensitivity and specificity of the IHC for EGFR
mutation also did not reach perfect to detect all sensitive
mutations. For clinical practice, molecular testing, for example:
DNA sequencing, for confirmation may be still necessary if IHC
shows negative result.
Five tumors (11.6%, 5 of 43) harbored L858R and two tumors
(6.5%, 2 of 31) harbored the E746-A750 deletion could not be
detected by IHC staining in the present study, a phenomenon which
has also been seen in previous studies [9,11]. One possible reason
may be the heterogeneous component of the cancers may have had
an effect, so a random tumor section may have included wild-type
EGFR cancer cells thereby missing the positive EGFR mutation
component. In addition, the long-term storage of the paraffin-
embedded specimens, as the biological nature may have changed
resulting in poor IHC staining. However, in this study we had use
pan-cytokeratin stains to confirm the quality of the studied specimens.
In conclusion, total EGFR expression should be included into
the interpretation of IHC stain of EGFR L858R antibody. IHC
staining of mutation-specific antibodies, which could be routinely
practiced in pathology laboratories, is useful to predict EGFR TKI
treatment outcome.
Supporting Information
Table S1 The genotype and immunohistochemistry
results of EGFR mutations.
(DOCX)
Table S2 Clinical practice index for the EGFR mutation-
specific antibodies of L858R (the corresponding table of
predictive probability is listed as Table S4).
(DOCX)
Table 5. Multivariate analysis of progression-free survival of
the 37 adenocarcinoma patients treated with EGFR TKIs.
Factors
Patient
Number
Univariate
analysis
Multivariate
analysis
p
value
HR
(95% CI)
p
value
Gender
Female 19
Male 18 0.841 1.04(0.22–4.88) 0.963
Smoking
Never smokers 23
Current/Former 14 0.776 0.88(0.17–4.46) 0.873
ECOG PS
0–1 28
2–4 9 0.001 5.52(2.04–14.95) 0.001
EGFR IHC*
Negative 15
Positive 22 0.012 0.29(0.12–0.68) 0.004
EGFR TKI
1
st-line 7
$2
nd-line 30 0.939 2.27(0.80–6.48) 0.126
EGFR = epidermal growth factor receptor, ECOG PS = Eastern Cooperative
Oncology Group performance status, HR = hazard ratio, CI = confidence
interval.
*Positive of EGFR IHC was according to our scoring method with the best AUC.
doi:10.1371/journal.pone.0023303.t005
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specific antibodies of E746-A750 deletion (the corre-
sponding table of predictive probability is listed as
Table S5).
(DOCX)
Table S4 The predictive probability of the correspond-
ing table for EGFR mutation-specific antibodies of
L858R (cut-off point =0.181).
(DOCX)
Table S5 The predictive probability of the correspond-
ing table for EGFR mutation-specific antibodies of
delE748-A750 (cut-off point =0.061).
(DOCX)
Table S6 The clinical characteristics and treatment
outcomes in the EGFR TKI-treated patients.
(DOCX)
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